Allergan Improves Safety Of Abicipar, But Not Enough Compared To Lucentis, Eylea

Allergan has been developing abicipar to provide less-frequent dosing in neovascular AMD, but despite success in reducing intraocular inflammation with a new formulation, the injectable still doesn’t match the safety of entrenched competitors.